Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop

On August 6, 2025, Alnylam Pharmaceuticals (ALNY) closed at $428.14, reflecting a 2.20% gain. The stock saw a trading volume of 0.50 billion, a 34.01% drop from the previous day, ranking 220th in market activity. Recent developments highlight strong performance in its second-quarter earnings and product sales.

Alnylam reported adjusted earnings of $0.32 per share for Q2 2025, surpassing the estimated loss of $0.59. Revenue reached $773.7 million, up 17% year-over-year, driven by robust sales of Amvuttra, which generated $150 million in its first full quarter. Analysts noted the drug’s potential for first-line dominance in treating ATTR cardiomyopathy, with Oppenheimer upgrading the stock to "Outperform" due to sales exceeding expectations.

Positive sentiment was further reinforced by analyst upgrades. Wolfe Research revised its rating from "Underperform" to "Peerperform," citing improved patient acquisition capabilities. The company also announced a presentation at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, signaling ongoing strategic momentum.

A backtest of a strategy purchasing the top 500 high-volume stocks and holding them for one day yielded a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the short-term impact of liquidity concentration and market volatility on high-volume stocks like ALNY.